The role of high-risk HPV testing in cervical cancer surveillance
| Autor: | Ritu Salani, L. Kwan, Joshua G. Cohen, Mae Zakhour, Chinmayi Aryasomayajula, M. Tandel, A. Chanana, Tiffany S. Lai |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Biopsy Uterine Cervical Neoplasms Routine practice Adenocarcinoma Carcinoma Adenosquamous Internal medicine Positron Emission Tomography Computed Tomography medicine Humans In patient Single institution Neoplasm Staging Cervical cancer business.industry Papillomavirus Infections Obstetrics and Gynecology Cancer Disease Management Middle Aged medicine.disease Carcinoma Neuroendocrine Oncology High risk hpv Colposcopy Carcinoma Squamous Cell Female Surveillance imaging Neoplasm Recurrence Local business |
| Zdroj: | Gynecologic oncology. 164(2) |
| ISSN: | 1095-6859 |
| Popis: | While high-risk HPV (hrHPV) testing is not formally recommended as a surveillance modality in patients with a history of cervical cancer, it is often performed in routine practice. It is unclear whether the presence of hrHPV infection after cervical cancer treatment is associated with recurrent disease.Patients with a cervical cancer diagnosis who were seen in a single institution between May 2012 and December 2019 were retrospectively identified. Squamous cell, adenocarcinoma, adenosquamous, and neuroendocrine histologies were included. Those with cancer progression within 3 months of treatment or 1 year of documented surveillance were excluded. Patients who had hrHPV testing performed were included in the primary outcome analysis.Of the 262 patients meeting inclusion criteria, 58 (22%) recurrences were diagnosed, and recurrence was most commonly detected by a surveillance imaging study (71%). Among the 169 patients that were tested for hrHPV during the surveillance period, 41 (24%) had at least one positive hrHPV test. Recurrent disease was diagnosed in 24 (14%). Of the 24 patients with recurrent disease, 5 (21%) had at least one positive hrHPV test during surveillance, versus 36 (24%) of 145 patients without recurrent disease (p = 0.67). No recurrences were detected by hrHPV testing.Positive hrHPV testing in the surveillance setting was not associated with cervical cancer recurrence but did lead to additional studies and procedures. Our findings do not support the routine use of hrHPV testing for the evaluation of cervical cancer recurrence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect